Overview
Message From The Chairperson
Center Laboratories started out as a drug manufacturer, but with the passage of time, it constantly expanded its business scope. Synergy effects and competitiveness of the group have been consolidated through investments and mergers & acquisitions. Our pursuit of economic benefits is paired with a deep awareness of the importance of sustainable corporate development. We therefore formulate relevant policies and goals in the three dimensions of economy, environment, and society (ESG) centered around our core operations as a drug manufacturer with reference to international standards and trends in the field of ESG and sustainable development. We rely on highly effective management and resource allocation to ensure steadfast progress on the path toward sustainable operations. Our ultimate goal is to set a paradigm for other group members to emulate.
Looking back on the past year, we have achieved brilliant results in our pharmaceutical and investment business. Our consolidated revenue reached NT$ 1.394 billion, which represents a record-breaking YoY growth of 81.69%. Amid a post-pandemic bounceback, the revenue of our pharmaceutical business rose to NT$ 950 million, accounting for a share of 68% of our total revenue. The successful merger with our subsidiary Glac Biotech in early 2023 contributed NT$ 444 million to our annual revenue.
In our pursuit of business growth, we do not neglect our social and environmental responsibility and proactively implement our business ethical values, namely “Innovation, Integrity, Professionalism, and the Common Good.” In the field of energy conservation and carbon reduction, we completed our heating coil and AHU (air handling unit) energy conservation projects paired with the conversion of our electric heaters to available hot water for heating to achieve reduced energy consumption. All these measures coupled with the replacement of obsolete, energy-intensive AC units with new energy-efficient units has resulted in a lower carbon footprint, energy cost savings, and a YoY energy intensity reduction of around 10%. In the social dimension, we champion our talent inclusion concept and are firmly committed to creating a friendly workplace characterized by diversity and equality. We show deep respect for the rights of female employees by offering flextime, parental leaves, and other benefit measures. We further encourage our female staff members to unleash their leadership potential. The high proportion of women in our management positions (68%) bears witness to these efforts. In addition, we show great concern for community health and safety with a focus on senior community members. This concern is reflected in the organization of a drug safety lecture tour for seniors with a total of 27 stops in 2023. This tour which featured 19 more lectures than last year’s event aimed to communicate accurate medication concepts and skills to elderly audiences and thereby enhance their life quality.
ESG Performance
2022
Governance & Economic
Revenues in Pharmaceutical BU
951
million2023 TWSE Corporate Governance Evaluation; top 6-20%.
2023
Environmental
Energy Intensity reduction
10%
2023
Social
Female in management team
67.6%
Hosting 27 seminars in Promoting medicines safety for elderly